Acadia Pharmaceuticals Inc. Company Profile

Aggregated data from the web about Acadia Pharmaceuticals Inc.

Company Name	Acadia Pharmaceuticals Inc.
Website	https://www.acadia-pharm.com
Snippet	ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020. Company Information. Annual Report Corporate Presentation. Scientific Publications. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014). Print page; Share.
Type	Public
Founded	1993
Revenue	$223.807 million (2018)
Website	acadia-pharm.com
Formerly	Receptor Technologies
Industry	Biopharmaceutical, Healthcare
Products	Pimavanserin
Traded as	NASDAQ: ACAD, Russell 2000 Component (2009)[1]
Key people	Stephen R. Davis, CEO, Mark R. Brann, CSO (c. 1997)[2]
Net income	$22.76 million(2011)
Headquarters	San Diego, CA, U.S.
Total assets	108.71 million (2012)
Operating income	$22.85 million (2011)
Number of employees	530

Acadia Pharmaceuticals Inc. is part of the United States company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.